135 related articles for article (PubMed ID: 27906723)
1. Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab.
Meredith RF; Torgue JJ; Rozgaja TA; Banaga EP; Bunch PW; Alvarez RD; Straughn JM; Dobelbower MC; Lowy AM
Am J Clin Oncol; 2018 Jul; 41(7):716-721. PubMed ID: 27906723
[TBL] [Abstract][Full Text] [Related]
2. Sensitization of tumor to ²¹²Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51.
Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1119-26. PubMed ID: 23200172
[TBL] [Abstract][Full Text] [Related]
3. Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy.
Garcia-Prada CD; Carmes L; Atis S; Parach A; Bertolet A; Jarlier M; Poty S; Garcia DS; Shin WG; Du Manoir S; Schuemann J; Tillement O; Lux F; Constanzo J; Pouget JP
J Nucl Med; 2023 Dec; 64(12):1956-1964. PubMed ID: 37857502
[TBL] [Abstract][Full Text] [Related]
4. ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.
Marth C; Vergote I; Scambia G; Oberaigner W; Clamp A; Berger R; Kurzeder C; Colombo N; Vuylsteke P; Lorusso D; Hall M; Renard V; Pignata S; Kristeleit R; Altintas S; Rustin G; Wenham RM; Mirza MR; Fong PC; Oza A; Monk BJ; Ma H; Vogl FD; Bach BA
Eur J Cancer; 2017 Jan; 70():111-121. PubMed ID: 27914241
[TBL] [Abstract][Full Text] [Related]
5. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors.
Yamamoto N; Nokihara H; Yamada Y; Shibata T; Tamura Y; Seki Y; Honda K; Tanabe Y; Wakui H; Tamura T
Invest New Drugs; 2017 Apr; 35(2):207-216. PubMed ID: 27928714
[TBL] [Abstract][Full Text] [Related]
7. Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients.
Amode R; Baroudjian B; Kowal A; Jebali M; Allayous C; Bagot M; Madjlessi N; Roux J; Viguier M; Basset Seguin N; Porcher R; Pagès C; Lebbé C
Melanoma Res; 2017 Apr; 27(2):110-115. PubMed ID: 27926587
[TBL] [Abstract][Full Text] [Related]
8. Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer.
Friedlander M; Banerjee S; Mileshkin L; Scott C; Shannon C; Goh J
Asia Pac J Clin Oncol; 2016 Dec; 12(4):323-331. PubMed ID: 27917619
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial.
Rouzier R; Gouy S; Selle F; Lambaudie E; Floquet A; Fourchotte V; Pomel C; Colombo PE; Kalbacher E; Martin-Francoise S; Fauvet R; Follana P; Lesoin A; Lecuru F; Ghazi Y; Dupin J; Chereau E; Zohar S; Cottu P; Joly F
Eur J Cancer; 2017 Jan; 70():133-142. PubMed ID: 27914243
[TBL] [Abstract][Full Text] [Related]
10. Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer.
Kotwinski P; Smith G; Cooper J; Sanders J; Ma L; Teis A; Kotwinski D; Mythen M; Pennell DJ; Jones A; Montgomery H;
PLoS One; 2016; 11(12):e0165262. PubMed ID: 27911951
[TBL] [Abstract][Full Text] [Related]
11. Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition.
Deppisch N; Ruf P; Eißler N; Lindhofer H; Mocikat R
Oncotarget; 2017 Jan; 8(3):4520-4529. PubMed ID: 27966460
[TBL] [Abstract][Full Text] [Related]
12.
Kwon LY; Scollard DA; Reilly RM
Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
[TBL] [Abstract][Full Text] [Related]
13. Phase I Trial: SABR and Ipilimumab-Letter.
Hiniker SM; Reddy SA; Swetter SM; Knox SJ
Clin Cancer Res; 2017 Jan; 23(1):320. PubMed ID: 28049160
[No Abstract] [Full Text] [Related]
14. An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts.
Chen Q; Weng Z; Lu Y; Jia Y; Ding L; Bai F; Ge M; Lin Q; Wu K
PLoS One; 2017; 12(1):e0168960. PubMed ID: 28045951
[TBL] [Abstract][Full Text] [Related]
15. Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.
Parikh A; Atreya C; Korn WM; Venook AP
J Natl Compr Canc Netw; 2017 Jan; 15(1):3-8. PubMed ID: 28040715
[TBL] [Abstract][Full Text] [Related]
16. Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab.
Friedman CF; Clark V; Raikhel AV; Barz T; Shoushtari AN; Momtaz P; Callahan MK; Wolchok JD; Chapman PB; Hellmann MD; Postow MA
J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 28040701
[TBL] [Abstract][Full Text] [Related]
17. A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma.
Brohl AS; Khushalani NI; Eroglu Z; Markowitz J; Thapa R; Chen YA; Kudchadkar R; Weber JS
J Immunother Cancer; 2016; 4():85. PubMed ID: 28031816
[TBL] [Abstract][Full Text] [Related]
18. Her2/neu Protein Expression and Oncogene Amplification in Gastric Carcinoma with Clinico-Pathological Correlation in Egyptian Patients.
Hadi AA; Hindawi AE; Hareedy A; Khalil H; Ashiry RA; Elia S; Sadek A; Magdy M; Atta R; Anas A; Bakr H; Hammam O
Open Access Maced J Med Sci; 2016 Dec; 4(4):535-542. PubMed ID: 28028387
[TBL] [Abstract][Full Text] [Related]
19. PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer.
van Loon J; Even AJG; Aerts HJWL; Öllers M; Hoebers F; van Elmpt W; Dubois L; Dingemans AC; Lalisang RI; Kempers P; Brans B; Winnepenninckx V; Speel EJ; Thunnissen E; Smits KM; Boellaard R; Vugts DJ; De Ruysscher D; Lambin P
Radiother Oncol; 2017 Feb; 122(2):267-273. PubMed ID: 28012793
[TBL] [Abstract][Full Text] [Related]
20. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy.
Vivar KL; Deschaine M; Messina J; Divine JM; Rabionet A; Patel N; Harrington MA; Seminario-Vidal L
J Cutan Pathol; 2017 Apr; 44(4):381-384. PubMed ID: 28000240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
